# Docetaxel Non-Squamous Non-Small Cell Lung Cancer Trial

> NCT07821684 is a phase 3 trial in non-squamous NSCLC; we pair it with docetaxel potency in ChEMBL, 1628 registered trials and EGFR dependency in DepMap.

Data as of 2026-11-14 · Published 2026-11-14 · Updated 2026-11-14 · https://bioq.bio/blog/en/docetaxel-nct07821684-non-squamous-non-small-cell-lung-cancer

![BioQ result page for the query docetaxel, showing ChEMBL targets, ClinicalTrials.gov studies and compound identity.](https://bioq.bio/blog/img/docetaxel-nct07821684-non-squamous-non-small-cell-lung-cancer/en/hero.webp)

AbbVie's phase 3 trial NCT07821684 compares telisotuzumab adizutecan with standard of care in previously treated, EGFR wildtype, non-squamous non-small cell lung cancer, and we checked what BioQ holds on docetaxel around it. BioQ returns 601 ChEMBL targets with docetaxel activity, 1628 registered docetaxel studies, and EGFR dependency in 224 of 1178 DepMap cell lines. The data are as of 2026-11-14.

## What we asked about the docetaxel non-squamous non-small cell lung cancer trial

The registry record for NCT07821684 is a phase 3 study sponsored by AbbVie. The title reads: intravenous telisotuzumab adizutecan versus standard of care in adults with previously treated, EGFR wildtype, locally advanced or metastatic non-squamous non-small cell lung cancer. The condition is non-squamous non-small cell lung cancer. The registered start date (2027-01-06) lies after the data date above, so this is a trial watch entry, not a results report.

The record we hold names the comparator only as "standard of care". We therefore do not claim from this record alone which drug the control arm receives. We use docetaxel as the reference drug for this trial and ask four things:

- How potent is docetaxel in measured ChEMBL data, and against which targets?
- How many other docetaxel trials are registered, and in which phases?
- What identity does the compound have across databases?
- Because the trial restricts to EGFR wildtype disease, how does EGFR behave as a dependency in cancer cell models?

## What BioQ returned

One query, docetaxel, plus a gene-level check on EGFR, drew on 5 distinct resources through 5 engine queries. The measured engine time was 2.12 seconds in total. Doing the same by hand would mean visiting each resource separately and reconciling identifiers between them.

![BioQ targets view for the query docetaxel listing ChEMBL targets with best pChEMBL values and exact measurement counts](https://bioq.bio/blog/img/docetaxel-nct07821684-non-squamous-non-small-cell-lung-cancer/en/targets.webp)
*Targets view for docetaxel: strongest measured ChEMBL targets with exact measurement counts.*

**Potency in ChEMBL.** Docetaxel maps to CHEMBL3545252 in ChEMBL. The database lists 601 targets for it, 600 of them with at least one exact measurement. The table shows the eight with the highest pChEMBL, which is the negative log10 of the molar potency.

| ChEMBL target | Gene | Best pChEMBL | Type | Exact measurements |
|---|---|---|---|---|
| CHEMBL3879801 | — | 10.94 | IC50 | 29 |
| CHEMBL398 | — | 10 | IC50 | 20 |
| CHEMBL612279 | — | 9.88 | IC50 | 1 |
| CHEMBL2032 | GHRHR | 9.85 | IC50 | 1 |
| CHEMBL612565 | — | 9.84 | IC50 | 1 |
| CHEMBL2366291 | — | 9.8 | IC50 | 1 |
| CHEMBL614733 | — | 9.8 | IC50 | 1 |
| CHEMBL2366139 | — | 9.79 | IC50 | 1 |

The highest value is 10.94, an IC50 for CHEMBL3879801 backed by 29 exact measurements. CHEMBL398 follows at 10.0 with 20 measurements. Most of the other rows rest on a single exact measurement. The gene column is empty for most of these targets, and the one gene shown is GHRHR.

**Other trials.** ClinicalTrials.gov matches 1628 studies with docetaxel as an intervention. By phase these are 369 in phase 1, 971 in phase 2 and 404 in phase 3. The counts cover all matched studies, and the table below is only a page of six.

| Trial | Phase | Status | Sponsor | Start | Enrollment |
|---|---|---|---|---|---|
| NCT02494713 | PHASE2 | TERMINATED | The University of Texas Health Science C | 2015-10 | 4 |
| NCT01783587 | PHASE1 | COMPLETED | Dana-Farber Cancer Institute | 2013-02 | 29 |
| NCT01446016 | PHASE2 | COMPLETED | The Methodist Hospital Research Institut | 2011-09 | 38 |
| NCT00005958 | PHASE2 | UNKNOWN | Amgen | 1999-10 | — |
| NCT07213674 | PHASE3 | RECRUITING | Amgen | 2025-11 | 750 |
| NCT00006120 | PHASE2 | UNKNOWN | GERCOR - Multidisciplinary Oncology Coop | 2000-05 | — |

Among the rows, NCT07213674 is a phase 3 study from Amgen that is recruiting, with an enrollment of 750. Two older records, from Amgen and GERCOR, have an unknown status and no enrollment listed.

**Compound identity.** PubChem lists docetaxel as CID 148123, InChIKey XCDIRYDKECHIPE-QHEQPUDQSA-N, with 21 synonyms and the same ChEMBL identifier as above. This is how a trial record, a potency row and a literature mention are tied to one compound.

**EGFR dependency.** The trial restricts to EGFR wildtype disease, so we looked at EGFR in DepMap (Chronos gene effect). Of 1178 cell lines, 224 are dependent, which is 19.0 percent. The mean gene effect is -0.294, and EGFR is not flagged as common essential.

| Lineage | Cell lines | Dependent | % dependent | Mean gene effect |
|---|---|---|---|---|
| Head and Neck | 77 | 51 | 66.2 | -0.702 |
| Prostate | 10 | 6 | 60 | -0.696 |
| Biliary Tract | 35 | 17 | 48.6 | -0.561 |
| Cervix | 18 | 7 | 38.9 | -0.434 |
| Esophagus/Stomach | 69 | 27 | 39.1 | -0.422 |

The five lineages with the highest share of dependent lines are Head and Neck (66.2 percent of 77 lines), Prostate (60.0 percent of 10), Biliary Tract (48.6 percent of 35), Esophagus/Stomach (39.1 percent of 69) and Cervix (38.9 percent of 18). A lung lineage does not appear in this top five. For context, the drug layer lists 118 drugs for EGFR; osimertinib has 188 trials by name and erlotinib 355.

## What it means and how to read it

The potency table describes biochemical and cellular measurements. A pChEMBL of 10.94 is a strong value on that scale, but a high number on one target does not describe what the drug does in a patient. Rows backed by a single exact measurement are weaker evidence than the row with 29. The empty gene column means those ChEMBL targets are not mapped to a gene symbol in this view, so we do not interpret them biologically.

The trial count shows that docetaxel is a heavily studied agent, with 404 phase 3 registrations alone. A new phase 3 study such as NCT07821684 therefore enters a crowded registry, and comparing its design with earlier studies means filtering by condition, line of therapy and biomarker status.

The EGFR numbers fit the trial's eligibility rule in one limited way. EGFR knockout reduces viability in a minority of cell lines (19.0 percent), and the effect is strongest in lineages other than lung. This says nothing about the trial's target or its outcome. It only helps explain why EGFR status is used to define a population.

## How to reproduce it in BioQ

1. Open BioQ and paste the query below into the search box.
2. Read the compound block first to confirm the identity (CID 148123, CHEMBL3545252).
3. Open the targets view and sort by pChEMBL, then check the count of exact measurements next to each value.
4. Open the trials view and filter by phase 3 and by status to see recruiting studies.
5. Run a second query on the gene EGFR to see the DepMap lineage table and the drug list.

```text
docetaxel
```

[Open this query in BioQ](https://bioq.bio/login?next=%2Fapp%23q%3Ddocetaxel)

Every returned block names its source and release, so each number can be traced back to ChEMBL, the ClinicalTrials.gov snapshot or DepMap.

## Limits: what the data do not show

- The registry title we hold says "standard of care" and does not name docetaxel as the comparator. Confirm the arms on the registry page before citing the trial as a docetaxel comparison.
- The trial's own drug, telisotuzumab adizutecan, is not covered by the blocks above. Its potency and target data are not part of this answer.
- The mechanism of action of docetaxel is not in the returned blocks, so we do not describe it here.
- pChEMBL values mix assay types and systems. They are not directly comparable to patient exposure or to response.
- DepMap measures knockout of EGFR in cell lines, not drug response, and a Chronos threshold is a named constant, not a biological boundary.
- Trial counts depend on how ClinicalTrials.gov matches intervention names, and a study can be counted under more than one phase label.
- Nothing here is medical advice, and no outcome data exist yet for NCT07821684.

## Data and method
The numbers on this page were read from the BioQ engine on 2026-11-14 (5 queries, 2.1 s of engine time in total). The tables are generated by code from the engine's answers; the text only restates them.

`/chembl_potency`, `/clinicaltrials`, `/compound`, `/depmap`, `/drugs`

## Sources
- A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (2027) — [https://clinicaltrials.gov/study/NCT07821684](https://clinicaltrials.gov/study/NCT07821684)

Run the same query yourself: [docetaxel](https://bioq.bio/login?next=%2Fapp%23q%3Ddocetaxel)

*For research use only. This page summarises public data and is not medical advice.*

BioQ is an AI search engine and agent with one goal: making biology research 100X faster. Ask in the web app, over the REST API, or from Claude, ChatGPT or Cursor through MCP.

## Queries used

- [`docetaxel`](https://bioq.bio/login?next=%2Fapp%23q%3Ddocetaxel)

## Frequently asked questions

### What is NCT07821684?

NCT07821684 is a phase 3 trial sponsored by AbbVie. It compares intravenous telisotuzumab adizutecan with standard of care in previously treated, EGFR wildtype, locally advanced or metastatic non-squamous non-small cell lung cancer. Its registered start of 2027-01-06 lies after the data date of 2026-11-14.

### How many docetaxel trials are registered on ClinicalTrials.gov?

BioQ matches 1628 studies with docetaxel as an intervention: 369 in phase 1, 971 in phase 2 and 404 in phase 3. The counts cover all matched studies as of 2026-11-14.

### What is the highest docetaxel pChEMBL in ChEMBL?

Among the 601 ChEMBL targets listed for docetaxel (CHEMBL3545252), the highest value shown is 10.94, an IC50 for CHEMBL3879801 with 29 exact measurements. The next value is 10.0 for CHEMBL398 with 20 exact measurements.

### Is EGFR a common essential gene in DepMap?

No. In DepMap, EGFR is dependent in 224 of 1178 cell lines (19.0 percent), with a mean Chronos gene effect of -0.294, and it is not flagged as common essential.

## Sources

- Trial: [A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer](https://clinicaltrials.gov/study/NCT07821684) (2027)
- Dataset: [ClinicalTrials.gov](https://clinicaltrials.gov/)
- Dataset: [PubChem](https://pubchem.ncbi.nlm.nih.gov/)
- Dataset: [DepMap CRISPR Chronos gene effect (24Q4)](https://depmap.org/portal/)
- Dataset: [Open Targets Platform; ChEMBL; Drug Repurposing Hub](https://platform.opentargets.org/)

> Results come from public databases as of the date shown and may change. BioQ gives research information, not medical advice.
